NCT05095545 - Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

August 7, 2019

Study Completion Date

August 30, 2019

Conditions

Influenza

Interventions

DRUG

AV5080

Hard gelatin capsules with a white body

OTHER

Placebo

Hard gelatin capsules with a white body

Trial Locations (10)

City polyclinic №10, Kazan'

Infectious Clinical Hospital No. 1 of the Moscow City Health Department, Moscow

GBUZ NO Infections Clinical Hospital No.2, Nizhny Novgorod

Podolsk City Clinical Hospital №3, Podolsk

City Hospital No. 1 n.a. ON. Semashko, Rostov-on-Don

City Clinical Hospital of Infectious Diseases No. 17, Saint Petersburg

City hospital №40, Saint Petersburg

Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Stavropol

Voronezh Regional Clinical Infectious Diseases Hospital, Voronezh

Medical Center for Diagnostics and Prevention Plus, LLC, Yaroslavl